| Affiliation: | (1) Surgery Branches, Center for Cancer Research of the National Cancer Institute, Bethesda, Maryland;(2) Medicine Branches, Center for Cancer Research of the National Cancer Institute, Bethesda, Maryland;(3) Radiation Oncology Branches, Center for Cancer Research of the National Cancer Institute, Bethesda, Maryland;(4) Laboratory of Pathology, Center for Cancer Research of the National Cancer Institute, Bethesda, Maryland;(5) Biostatistics and Data Management Section, Center for Cancer Research of the National Cancer Institute, Bethesda, Maryland;(6) Department of Radiology, Clinical Center, National Institutes of Health, Bethesda, Maryland;(7) Rehabilitation Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland;(8) Department of Surgery, Walter Reed Army Medical Center, Washington, DC;(9) Surgery Branch, National Cancer Institute, Bldg. 10, Rm. 2B38, Bethesda, MD, 20815 |
| Abstract: | Background: Preoperative chemotherapy for stage II breast cancer may reduce locoregional tumors and provides initial treatment for systemic micrometastases. We conducted a prospective, randomized trial to evaluate the ability of intensive preoperative chemotherapy to enhance the outcome of this approach.Methods: Patients with clinical stage II breast cancer (T2N0, T1N1, and T2N1) were prospectively randomized to receive either preoperative or postoperative chemotherapy with five 21-day cycles of fluorouracil, leucovorin calcium, doxorubicin, and cyclophosphamide (FLAC)/granulocyte-colony-stimulating factor. Local therapy consisted of modified radical mastectomy or segmentectomy/axillary dissection/breast radiotherapy, according to patient preference.Results: Fifty-three women were randomized (26 preoperative chemotherapy and 27 postoperative chemotherapy). The objective clinical response rate of the primary tumor to preoperative chemotherapy was 80%, and the pathologic complete response rate was 20%. Preoperative chemotherapy reduced the overall incidence and number of axillary lymph node metastases. There was no difference in the use of breast-conserving local therapy between the two treatment arms. There were 20 local/regional or distant recurrences (9 preoperative and 11 postoperative). There was no difference in the overall or disease-free survival between the preoperative and postoperative chemotherapy arms.Conclusions: Preoperative FLAC/granulocyte-colony-stimulating factor chemotherapy was effective against local/regional tumors in stage II breast cancer but was otherwise comparable to postoperative chemotherapy. |
